PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer.

iScience · 2024 · PMC10897912 · PMID 38414861

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The mean MAF in the non-responders was higher than that in the responders in post-NACT ctDNA (p = 0.0721), not in pre-NACT ctDNA (p = 0.5967), although the difference in the post-NACT ctDNA did not reach statistical significance ( Figure 1 D).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.